Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
|Articles|February 15, 2003
- BioPharm International-02-01-2003
- Volume 16
- Issue 2
Becoming a Partner of Choice and Evaluating Prospective Alliances
Author(s)Jan Heybroek, David Wallis
by David Wallis, Dechert and Jan Heybroek Whether you're on the inlicensing or outlicensing side of a collaboration, attention must be paid to putting forth the right image and learning about your prospective partners before the alliance is struck.
Advertisement
Articles in this issue
over 23 years ago
Guest Editorial: Maybe You Need a Corporate Marriage Counselorover 23 years ago
Inside Washington: AIDS Prevention Campaign Spotlights Biotechover 23 years ago
Survival Strategies: Keeping Tabs on Trainingover 23 years ago
Outsourcing Outlook: Contract Services' Crystal BallAdvertisement
Related to this article
EA2251, the 7th registrational trial of ivonescimab, will test it plus chemotherapy vs pembrolizumab or durvalumab regimens in first-line BTC.
Roche will take ex-China development of Hansoh’s two preclinical ADCs and multiple programs against Roche-proposed targets once Hansoh completes global phase 1a trials. The deal includes $400 million upfront and more than $15 billion in potential milestones.
When large pharmaceutical companies deprioritize drug candidates, smaller developers may license or acquire them, but due diligence, deal structure, and trial planning determine whether a program can move forward.
Advertisement
Advertisement
Trending on BioPharm International
1
Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
2
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
3
FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease
4
The BioPharm Brief: Gilead’s Oral IL-23R Bet, Roche’s Trispecific Deal, and Treasury’s Biotech Investment Proposal
5